Table 5.
Effect of the probiotic treatment with Ligilactobacillus salivarius CECT 30632 on the number of gout episodes and the use of hyperuricemic- or gout-related medication during the study.
| Control group (n = 15) | Probiotic group (n = 15) | p-value | |
|---|---|---|---|
| n (%) | n (%) | ||
| Number of gout episodes during the study | |||
| 0 | 2 (13) | 10 (67) | 0.006a |
| 1 | 8 (53) | 5 (33) | |
| 2 | 4 (27) | - | |
| 3 | 1 (7) | - | |
| Use of allopurinol | |||
| No | 0 | 12 (80) | <0.001b |
| Yes | 15 (100) | 3 (20) | |
| Use of colchicine | |||
| No | 1 (7) | 10 (67) | <0.001b |
| Yes | 14 (93) | 5 (33) | |
| Use of ibuprofen and similar NSAIDs | |||
| No | 2 (13) | 10 (67) | 0.004b |
| Yes | 13 (93) | 5 (33) | |
aThe Freeman–Halton extension of the fisher exact probability test for a 2 × 4 contingency table. bFisher exact probability test (one-tailed). NSAIDs, non-steroidal anti-inflammatory drugs.